Anixa Biosciences (ANIX) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

Anixa Biosciences Inc (ANIX) Prix de l'Action, Cotation, Actualités et Historique

ANIXNASDAQ

Trade with Public

Trade with Public

$2.61

-0.06-2.25%

Dern. MÀJ: Oct 20, 7:38 AM

$2.61

-0.06-2.25%

AperçuActualités Prévisions de résultats Événements Objectifs de cours Données financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

-

Clôture

$2.61

Volume / Moy.

190.00 / 291.79K

Fourchette Journalière

- - -

Plage 52 Sem.

2.32 - 5.46

Capitalisation Boursière

$90.73M

Ratio P/E

-

Rendement des Dividendes

-

Échange

NASDAQ

RSI

38

Intérêt à Découvert

4.1%

Jours pour Couvrir

3.69

Actualités Récentes de Anixa Biosciences Inc

EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues

Anixa Biosciences shares new data from its ovarian cancer trial, showing patients lived longer than expected with no serious safety concerns, as regulators approved a major dose increase.

Vandana Singh

Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why

Anixa Biosciences shares surged in after-hours trading after presenting clinical trial data for its investigational breast cancer vaccine.

Mohd Haider

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

Anixa secures USPTO patent for its breast cancer vaccine using α-lactalbumin, enhancing its IP portfolio and expanding future immunotherapy options.

Vandana Singh

EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer vaccines, with U.S. trials planned.

Vandana Singh

EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development.

Vandana Singh

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

-7.38M

Flux de Trésorerie d'Investissement (TTM)

2.06M

Flux de Trésorerie de Financement (TTM)

5.22M

Flux de Trésorerie Libre (TTM)

-7.38M

Dépenses en Capital (TTM)

-

Variation Nette de la Trésorerie (TTM)

-97.00K

Tendances et prévisions des analystes

1

juin

1

sept.

Acheter

Conserver

Vendre

Vente forte

Évaluation et prévisions des analystes

4.0

Acheter

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

$77.39M

Ratio P/E (TTM)

-

Ratio P/E (FWD)

-

Ratio PEG (TTM)

-

Ratio P/S (TTM)

-

Ratio P/B (TTM)

6.29

Rendement des Bénéfices % (TTM)

-12.21%

Rendement des Bénéfices % (FWD)

-

EV / EBITDA (TTM)

-

Prix / EBITDA (TTM)

-

Prix / Flux de Trésorerie Libre (TTM)

-

Valeur Comptable / Action

$0.42

Dette Entreprise

Dette Totale

-

Dette à Long Terme

-

Émission de Dette à Long Terme (TTM)

-

Remboursement de la Dette à Long Terme (TTM)

-

Trésorerie Totale

$1.40M

Dette sur Capitaux Propres

0.01

Émission de Dette (TTM)

-

Remboursement de la Dette (TTM)

-